Neuren Pharmaceuticals Ltd has released a press release.
Q2 2024 update
Filed with ASX ·
On 6ix: 6ix.com/news/q2-2024-update
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Phase 2 trial shows significant improvements in Pitt Hopkins
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
- Q1 2024 quarterly activity and cash flow report
- Trofinetide accepted for Priority Review by Health Canada
- Neuren reports profit of $157 million for 2023
Later from Neuren Pharmaceuticals
- Phase 2 trial shows significant improvements in Angelman
- NEU continues PMS P3 preparations after positive FDA meeting
- DAYBUE receives marketing authorization in Canada
- PRV sold for US$150m - Neuren to receive one third
- Q3 2024 update
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals